Effect of Physicochemical Properties of Ophthalmic Formulations on Ocular Bioavailability Program
Page 2

Furthermore, it is also noted that suitable bioequivalence methods are lacking for many generic ophthalmic formulations, including suspensions and emulsions. Therefore an investigation of the relationship between various physicochemical properties and their effect on ocular bioavailability will help the FDA in establishing guidelines for the determination of bioequivalence of ophthalmic suspensions and emulsions.

The scope of the program will cover two types of inquiries:

a) In vitro study – Formulations with different physicochemical properties are manufactured using a selected steroid and characterized in vitro. Drug release and stability tests are conducted to understand how differences in physicochemical properties may affect ocular bioavailability.

b) In vivo study – Formulations selected based on the results of the in vitro study are tested in an animal model. A pharmacokinetic study should be conducted by assessing the ocular distribution of the steroid in various eye tissues and organs at various time points.

In order to support these initiatives, the Food and Drug Administration is set to administer funds in the amount of $400,000.

The institutions and organizations who will be deemed eligible to submit an application under this program are the following:

a) Private and Public Non-profit entities

b) State and Local Governments

c) Indian Tribal Governments and Organizations

d) Faith-based Organizations

e) Community-based Organizations

f) Institutions of Higher Education

g) Private and Public Colleges and Universities

h) Independent School Districts

The United States Department of Health and Human Services, the mother agency funding the Effect of Physicochemical Properties of Ophthalmic Formulations on Ocular Bioavailability Program, is country's premiere agency for protecting the health of all Americans and providing essential human services, especially to those who medically challenged and vulnerable.

Effect of Physicochemical Properties of Ophthalmic Formulations on Ocular Bioavailability Program
  Back to Page 1

About The Author Iola Bonggay is an editor of TopGovernmentGrants.com one the the most comprehensive Websites offering information on government grants and federal government programs. She also maintains Websites providing resources on environmental grants and grants for youth programs.

Additional Resources

category - Health Grants

Targeting Persistent HIV Reservoirs Grant Program
In keeping with this mission, the National Institutes of Health has recently formed a partnership with the National Institute of Allergy and Infectious Diseases (NIAID) and the National Institute of Mental Health (NIMH) in order to establish the Targeting Persistent HIV Reservoirs Grant Program.

---

Advanced Education Nursing Traineeship Program
In keeping with this mission, the Health Resources and Services Administration has recently constituted the Advanced Education Nursing Traineeship Program wherein it aims to increase the number of primary care providers through the provision of training programs to nurses who are pursuing advanced degrees primary care nurse practitioners (NP) or nurse-midwives.

---

Medical Tropical Research Laboratory Program Infectious Disease Research Award
AFRIMS has recently announced the WRAIR Medical Tropical Research Laboratory Program(MTRLP) Infectious Disease Research Award(IDRA), a funding opportunity which solicits proposals that aim to tackle basic, preclinical and clinical research of emerging infectious diseases in Thailand and a certain region in Southeast Asia.

---

Development of Therapeutics and Diagnostics for Biodefense Program
The National Institutes of Health, in partnership with the National Institute of Allergy and Infectious Diseases(NIAID), has established the Development of Therapeutics and Diagnostics for Biodefense Program in an attempt to seek research proposals that desire to support the development of lead candidate diagnostics or therapeutics against NIAID Category A, B, or C priority agents.

---